Actively Recruiting
Evaluation of Safety, Tolerability, and Early Effects of YK012 IV Infusions Every 2 Weeks in Adults with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Led by Excyte Biopharma Ltd · Updated on 2026-07-17
48
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating YK012, a bispecific antibody targeting CD19 on B cells and CD3 on T cells, in adults with relapsed or refractory B-cell non-Hodgkin lymphoma RR B-NHL. This first-in-human Phase 1 trial aims to assess the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of YK012 in this patient population. The study provides foundational data for further clinical development of YK012. Participants receive YK012 through intravenous infusion every two weeks within 4-week treatment cycles. Treatment continues until disease progression, intolerable side effects, withdrawal, loss to follow-up, death, or after completing up to six cycles. This sequential study monitors participants closely throughout the treatment period. During the study, participants undergo evaluations including safety assessments for adverse events and dose-limiting toxicities, pharmacokinetic measurements up to 12 weeks, and efficacy assessments such as tumor response and progression-free survival up to 24 weeks. Additional laboratory tests monitor immune cell counts and cytokine levels. Safety monitoring extends to 28 days after treatment ends, with the total study duration lasting until 2028.
CONDITIONS
Brief Title
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
Research Team
Y
Yuankai Shi, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here